OBJECTIVE: Because of the dose-dependent increase in bleeding complications, the intraoperative administration of fibrinolytic agents is limited. This limitation impairs the efficacy of fibrinolytic therapy because low-dose fibrinolysis often fails in the treatment of complex deep venous thrombosis (DVT). The aim of this study was to investigate the efficacy and safety of intraoperative high-dose fibrinolytic therapy for extended DVT, which was performed with the regional hyperthermic fibrinolytic perfusion (RHFP) technique. METHODS: From January 1993 to June 2001, in 53 patients with extended DVT, unsuccessful venous thrombectomy (recanalization, <50%) was followed by RHFP with 0.5 mg/kg of body weight of recombinant tissue plasminogen activator. The extent of thrombosis was documented before, during (after the surgical thrombectomy), and after (between postoperative days 2 and 5) surgery with phlebography and was quantified with the Marder score. Intraoperative and postoperative complications were recorded prospectively. RESULTS: After RHFP, a recanalization was achieved in 64 of 146 venous segments (43.8%) that were still occluded despite thrombectomy. Eighty-two segments (56.2%) remained occluded. Compared with the preoperative phlebography, 32 patients (60.3%) had a successful recanalization (>50%). Eleven patients (20.8%) showed minimal and 10 patients (18.9%) no recanalization. No lethal complications occurred. One patient (1.9%) had pulmonary embolism develop, and two patients (3.8%) had bleeding complications develop. CONCLUSION: With the intraoperative use of hyperthermia-assisted high-dose fibrinolysis, improvement of the results of mechanical thrombectomy of extended DVT was possible. The RHFP protected against systemic side effects of the fibrinolysis and show a high safety of application.
OBJECTIVE: Because of the dose-dependent increase in bleeding complications, the intraoperative administration of fibrinolytic agents is limited. This limitation impairs the efficacy of fibrinolytic therapy because low-dose fibrinolysis often fails in the treatment of complex deep venous thrombosis (DVT). The aim of this study was to investigate the efficacy and safety of intraoperative high-dose fibrinolytic therapy for extended DVT, which was performed with the regional hyperthermic fibrinolytic perfusion (RHFP) technique. METHODS: From January 1993 to June 2001, in 53 patients with extended DVT, unsuccessful venous thrombectomy (recanalization, <50%) was followed by RHFP with 0.5 mg/kg of body weight of recombinant tissue plasminogen activator. The extent of thrombosis was documented before, during (after the surgical thrombectomy), and after (between postoperative days 2 and 5) surgery with phlebography and was quantified with the Marder score. Intraoperative and postoperative complications were recorded prospectively. RESULTS: After RHFP, a recanalization was achieved in 64 of 146 venous segments (43.8%) that were still occluded despite thrombectomy. Eighty-two segments (56.2%) remained occluded. Compared with the preoperative phlebography, 32 patients (60.3%) had a successful recanalization (>50%). Eleven patients (20.8%) showed minimal and 10 patients (18.9%) no recanalization. No lethal complications occurred. One patient (1.9%) had pulmonary embolism develop, and two patients (3.8%) had bleeding complications develop. CONCLUSION: With the intraoperative use of hyperthermia-assisted high-dose fibrinolysis, improvement of the results of mechanical thrombectomy of extended DVT was possible. The RHFP protected against systemic side effects of the fibrinolysis and show a high safety of application.